Clinical Trial Update: Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing the effectiveness, tolerability and safety of rasagiline in early Parkinson's disease patients not treated with levodopa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: Teva Neuroscience, Inc. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED